Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109336 | 1.00 | CTSK (0.43) | CTSKCTSLCTSSPOLBAKT1 | |
| SCHEMBL10310638 | 1.00 | CTSK (0.43) | CTSKCTSLCTSSPOLBAKT1 | |
| SCHEMBL18109338 | 1.00 | CTSK (0.43) | CTSKCTSLCTSSPOLBAKT1 | |
| SCHEMBL28067000 | 1.00 | CTSK (0.43) | CTSKCTSLCTSSPOLBAKT1 | |
| SCHEMBL15630764 | 0.90 | AKT1 (0.39) | CTSKCTSLCTSSAKT1RIPK1 | |
| SCHEMBL8624830 | 0.87 | POLB (0.42) | CTSKCTSLCTSSPOLB | |
| SCHEMBL7376886 | 0.87 | POLB (0.42) | CTSKCTSLCTSSPOLB | |
| SCHEMBL7373925 | 0.87 | POLB (0.42) | CTSKCTSLCTSSPOLB | |
| SCHEMBL30497214 | 0.86 | GPR88 (0.38) | CTSLCTSSAKT1RIPK1 | |
| SCHEMBL15630730 | 0.86 | AKT1 (0.39) | CTSLCTSSAKT1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3722297-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3321265-B1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10285990-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3321265-A1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3097102-B1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670205-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| CN-103608347-B | Imidazopyridine | ASTELLAS PHARMA INC. (JP) | 2016-04-27 | — | — | CN | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281627-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CTSK 3582/4885CTSL 2973/4885CTSS 4368/4885 |
| US-10285990-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | CTSK 3582/4885CTSL 2973/4885CTSS 4368/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CTSK 3582/4885CTSL 2973/4885CTSS 4368/4885 |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | GUCY1A1, PDE2A, GUCY1A2 | CTSK 4036/4885CTSL 4254/4885CTSS 4449/4885 |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CTSK 3582/4885CTSL 2973/4885CTSS 4368/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CTSK 3582/4885CTSL 2973/4885CTSS 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.